Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-06-19
2007-06-19
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S009100, C530S329000, C530S317000, C435S007100, C424S009100
Reexamination Certificate
active
10027015
ABSTRACT:
Methods, compositions and devices are disclosed for use in growing new blood vessels to restore or improve blood flow to ischemic tissues and organs of the body. Compositions comprising IGD peptides, particularly GGIGDGG, are able to induce migration in human endothelial cells and promote vessel formation in an in vitro model assay system.
REFERENCES:
patent: 4699788 (1987-10-01), Catsimpoolas et al.
patent: 4895838 (1990-01-01), McCluer et al.
patent: 4900673 (1990-02-01), Harper et al.
patent: 4950483 (1990-08-01), Ksander et al.
patent: 5116738 (1992-05-01), Wang et al.
patent: 5141905 (1992-08-01), Rosen et al.
patent: 5187076 (1993-02-01), Wozney et al.
patent: 5219576 (1993-06-01), Chu et al.
patent: 5318957 (1994-06-01), Cid et al.
patent: 5328695 (1994-07-01), Lucas et al.
patent: 5371191 (1994-12-01), Poser et al.
patent: 5459047 (1995-10-01), Wozney et al.
patent: 5470831 (1995-11-01), Whitman et al.
patent: 5543392 (1996-08-01), Tomita et al.
patent: 5543394 (1996-08-01), Wozney et al.
patent: 5595722 (1997-01-01), Grainger et al.
patent: 5616490 (1997-04-01), Sullivan et al.
patent: 5631142 (1997-05-01), Wang et al.
patent: 5635372 (1997-06-01), Celeste et al.
patent: 5637480 (1997-06-01), Celeste et al.
patent: 5656587 (1997-08-01), Sporn et al.
patent: 5661007 (1997-08-01), Wozney et al.
patent: 5677276 (1997-10-01), Dickerson et al.
patent: 5703043 (1997-12-01), Celeste et al.
patent: 5705477 (1998-01-01), Sporn et al.
patent: 5846770 (1998-12-01), LaVallie et al.
patent: 5849880 (1998-12-01), Wozney et al.
patent: 5854207 (1998-12-01), Lee et al.
patent: 5866364 (1999-02-01), Israel et al.
patent: 5928940 (1999-07-01), Sampath et al.
patent: 5932216 (1999-08-01), Celeste et al.
patent: 5965403 (1999-10-01), Celeste et al.
patent: 5972884 (1999-10-01), Cohen et al.
patent: 5981489 (1999-11-01), Stevenson et al.
patent: 5994094 (1999-11-01), Hötten et al.
patent: 6051648 (2000-04-01), Rhee et al.
patent: 6120760 (2000-09-01), Hötten et al.
patent: 6124273 (2000-09-01), Drohan et al.
patent: 6150328 (2000-11-01), Wang et al.
patent: 6177406 (2001-01-01), Wang et al.
patent: 6197550 (2001-03-01), Hötten et al.
patent: 6211157 (2001-04-01), Benedict et al.
patent: 6468960 (2002-10-01), Lukanidin et al.
patent: 6498142 (2002-12-01), Sampath et al.
patent: 2002/0025340 (2002-02-01), Dyer
patent: 2002/0040004 (2002-04-01), Benedict et al.
patent: 2003/0022828 (2003-01-01), Akella et al.
patent: 2003/0104977 (2003-06-01), Ripamonti et al.
patent: 0433225 (1991-06-01), None
patent: 0516901 (1992-12-01), None
patent: 0747066 (1996-12-01), None
patent: WO 97/41880 (1997-11-01), None
patent: WO 99/02674 (1999-01-01), None
patent: WO 99/31136 (1999-06-01), None
patent: WO 99/57146 (1999-11-01), None
patent: WO00/55206 (2000-09-01), None
patent: WO 02/00244 (2002-01-01), None
patent: WO 02/47713 (2002-06-01), None
patent: WO 03/060076 (2003-07-01), None
Carron et al.,Cancer Research58:1930-1935 (May 1998).
Shpiro et al.,Mol. BioSyst. 1:318-320 (Aug. 26, 2005).
Cuevas et al., “Fibroblast Growth Factor Protects the Kidney Against Ischemia-Reperfusion Injury,”Eur. J. Med. Res., 4:403-10, 1999.
Folkman, “Angiogenic Therapy of the Human Heart,”Circulation, 97:628-29, 1998.
Freed et al., “Neocartilage formation in vitro and in vivo using cells cultured on synthetic biodegradable polymers,”J. Biomed. Mater. Res., 27:11-23, 1993.
Freedman and Isner, “Therapeutic Angiogenesis for Ischemic Cardiovascular Disease,”Molecular and Cellular Cardiology, 33;379-93, 2001.
Hammerman, “Growth Factors in Renal Development,”Seminars in Nephrology, 15:291-99, 1995.
Hirschberg et al., “Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure,”Kidney International, 55:2423-32, 1999.
Kawa-uchi et al., “Fibroblast growth factor enhances expression of TGFβ-stimulated-clone-22 gene in osteoblast-like cells,”Endocrine, 3:833-37, 1995.
Laham et al., “Intrapericardial Delivery of Fibroblast Growth Factor-2 Induces Neovascularization in a Porcine Model of Chronic Myocardial Ischemia,”J. Pharmacol. Exp. Ther., 292:795-802, 2000.
Mueller et al., “Myocardial angiogenesis induction with bone protein derived growth factors (animal experiment),”Swiss Med. Wkly, 131:23-25, 2001.
Nakaoka et al., “Inhibition of Rat Vascular Smooth Muscle Proliferation In Vitro and In Vivo by Bone Morphogenetic Protein-2,”J. Clin. Invest., 100:2824-32, 1997.
Nishida et al., “Adenovirus-Mediated Gene Transfer to Nucleus Pulposus Cells,”Spine, 23:2437-42, 1998.
Parsons-Wingerter et al., “A novel assay of angiogenesis in the quail chorioallantoic membrane: stimulation by bFGF and inhibition by angiostatin according to fractal dimension and grid intersection,”Microvasc. Res., 55:201-14, 1998.
Prochazka et al., “Epidermal Growth Factor and Insulin Growth Factor I Increase FSH-Stimulated Expansion of Porcine Cumulus Cells in Serum-free Medium,”J. Reproduction and Fertility, 25:64, 2000.
Ramoshebi and Ripamonti, “Osteogenic protein-1, a bone morphogenetic protein, induces angiogenesis in the chick chorioallantoic membrane and synergizes with basic fibroblast growth factor and transforming growth factor-beta 1,”Anat. Rec., 259:97-107, 2000.
Sakaguchi et al., “A Combination of EGF and IGF-1 Accelerates the Progression of Meiosis in Bovine Follicular Oocytes In Vitro and Fetal Calf Serum Neutralizes the Acceleration Effect,”Theriogenology, 54:1327-42, 2000.
Schumacher et al., “Induction of Neoangiogenesis in Ischemic Myocardium by Human Growth Factors,” Circulation, 97:645-50, 1998.
Stelnicki et al., “Bone Morphogenetic Protein-2 Induces Scar Formation and Skin Maturation in the Second Trimester Fetus,”Plastic and Reconstructive Surgery, 101:12-19, 1998.
Vukicevic et al., “Osteogenic Protein-1 (Bone Morphogenetic Protein-7) Reduces Severity of Injury After Ischemic Acute Renal Failure in Rat,”J. Clin. Invest., 102:202-14, 1998.
Wiley and Cunningham, “Epidermal Growth Factor Stimulates Fluid Phase Endocytosis in Human Fibroblasts Through a Signal Generated at the Cell Surface,”J. Cellular Biochem., 19:383-94, 1982.
Yamamoto et al., “Histologic evidence that basic fibroblast growth factor enhances the angiogenic effects of transmyocardial laser revascularization,”Basic Res. Cardiol., 95:55-63, 2000.
Yamashita et al., “Growth/Differentiation Factor-5 Induces Angiogenesis In Vivo,”Exper. Cell Res., 235:218-26, 1997.
Yonggang et al., “Percutaneous injection of bone morphogenetic protein and polyvinyl pyrrolidone composite,”J. Xi'an Medical University, 22:132-33, 2001.
PCT Search Report from PCT/US02/41484, dated Aug. 12, 2004.
Chernousov et al., “Role of the I-9 and III-1 Modules of Fibronectin in Formation of an Extracellular Fibronectin Matrix,”J. Biol. Chem., 266:10851-58, 1991.
Akella Rama
Ranieri John
Kam Chih-Min
Williams Morgan & Amerson P.C.
Zimmer Orthobiologics, Inc.
LandOfFree
Compositions and methods for promoting myocardial and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for promoting myocardial and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for promoting myocardial and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3811594